Stock Events

Stock Events

Search...

Mirum Pharmaceuticals

M$0

22

+M$0+0% Wednesday 11:30

Statistics

Day High

629.79

Day Low

629.79

52W High

629.79

52W Low

426.02

Volume

0

Avg. Volume

0

Mkt Cap

14.3B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.94

-1.37

-0.81

-0.24

Expected EPS

-0.431434

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MIRM.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in developing treatments for liver diseases, directly competing with Mirum's focus on rare liver conditions.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals works on RNAi therapeutics for a variety of conditions, including liver diseases, competing in the same therapeutic space as Mirum.

Gilead Sciences

Gilead Sciences has a broad portfolio that includes treatments for liver diseases, positioning it as a competitor in the hepatology market.

AbbVie has a diverse drug portfolio that includes treatments for liver diseases, making it a competitor in the same market as Mirum.

Pfizer has a wide range of pharmaceutical products, including treatments for liver conditions, competing with Mirum Pharmaceuticals.

Novartis AG engages in the research, development, and marketing of healthcare products, including liver disease treatments, which puts it in competition with Mirum.

Merck & Co., Inc. offers a variety of healthcare products and services, including treatments for liver diseases, making it a competitor.

AstraZeneca operates in multiple therapeutic areas, including liver diseases, directly competing with Mirum's product offerings.

Bristol-Myers Squibb

Bristol Myers Squibb has a diverse portfolio in healthcare, including liver disease treatments, positioning it as a competitor to Mirum Pharmaceuticals.

About

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Show more...

CEO

Mr. Christopher Peetz

Employees

194

Country

United States

ISIN

US6047491013

Listings